Harrow, Inc. announced a licensing agreement with Formosa Pharmaceuticals, acquiring the exclusive U.S. commercial rights for BYQLOVI (clobetasol propionate ophthalmic suspension) 0.05%. BYQLOVI is an FDA-approved ophthalmic steroid for the treatment of post-operative inflammation and pain following ocular surgery, and it is the first new ophthalmic steroid in its class in over 15 years.
BYQLOVI is formulated using Formosa's proprietary APNT nanoparticle technology, offering compelling efficacy, safety, and patient-friendly dosing. Clinical studies showed high rates of pain relief (77% and 85% of patients reporting no pain at Day 4) and inflammation clearance (33% and 30% with zero cell counts at Day 8). It also demonstrated a low incidence of elevated intraocular pressure at 1.4%.
Mark L. Baum, CEO of Harrow, stated that BYQLOVI has the potential to shift the paradigm in the multi-billion-dollar U.S. post-surgical care ophthalmic segment, which exceeds 7 million annual ophthalmic surgeries. Harrow expects BYQLOVI to be available in the fourth quarter of 2025, representing a significant new revenue stream for the company.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.